María Natalia GaNdur Quiroga, Chief of the Division of Genitourinary Medical Oncology at the Angel H. Roffo Oncology Institute, shared a post on X:
“GU26 – Day Highlights Prostate Cancer
Today was not about incremental updates. It was about structural shifts in how we think.
Biology is finally driving decisions
- PTEN-deficient mHSPC – AKT pathway targeting (CAPItello-281)
- PARPi sequencing in BRCA/ATM-altered disease
- ctDNA emerging as strongly prognostic
We are moving from ‘hormone-sensitive vs resistant’ to molecularly contextualized disease states.
Radioligand therapy is accelerating
- Alpha-emitters showing deep PSA50 responses
- OS signals maturing in mCRPC
- Sequencing will determine impact
The next battlefield isn’t activity. It’s implementation.
PCWG4 redefining progression
- Imaging ≠ automatic failure
- Multimodal endpoints (PSA + imaging + ctDNA + PROs)
- Context-dependent interpretation
Trial design is evolving to match biologic complexity.
Overtreatment vs undertreatment tension
- Salvage RT + ADT: PSA-driven nuance
- Frailty ≠ barrier to ADT+ARPI
- 50% attrition crisis in mCRPC – many never reach 2L
The biggest threat may not be resistance. It may be loss of opportunity.
Prostate cancer care =
- Biomarker selection
- Strategic sequencing
- Timing optimization
- Toxicity balance
- Access planning
Not just drug choice. This is the transition from escalation to orchestration.”
Other articles about ASCO GU26 on OncoDaily.
